A Phase 2 interventional study of JNJ-77242113 in Plaque Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 60 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Psoriasis by Johnson & Johnson — 3 open to participants now, 12 under way, 7 of them phase 3. Psoriasis · Johnson & Johnson.
Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 29th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2022, is one of 12 in phase 2, and was the 65th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →3 of the 76 studies in Psoriasis by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:
Janssen-Cilag Kft. · Sites in Hungary
Ages 18+
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
Janssen Research & Development, LLC · Sites in Romania
Ages 18+
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 36 · Phase 4 4
First in 2002; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 227 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 222 across the 58 interventional studies, 363 across the 18 observational. Of the 64 that completed or were terminated, 33 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
1 of the studies in Psoriasis by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 76 studies in Psoriasis by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis.
The populations of people living with moderate to severe psoriasis is approximately 3.5 billion which are mostly managed with topical and conventional therapies. JNJ-77242113, investigational drug, targets the immune responses in the body and skin which impacts diseases, such as psoriasis and this study evaluates JNJ-77242113 as options of advanced therapies in moderate to severe plaque psoriasis. This is a long-term extension study of JNJ-77242113 in eligible participants who have completed the Week 16 visit of the originating Study 77242113PSO2001. The total duration of this study will be up to 40 weeks which will include a 36-week treatment period, and a 4-week safety follow-up period after the last study intervention administration. Safety will be assessed by adverse events (AEs), clinical safety laboratory assessments, electrocardiograms (ECGs), vital signs and physical examinations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants originally randomized to JNJ-77242113 Dose 1 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 QD from Week 0 through Week 36 in this study.
Drug: JNJ-77242113
Participants originally randomized to JNJ-77242113 Dose 2 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 2 QD from Week 0 through Week 36 in this study.
Drug: JNJ-77242113
Participants originally randomized to JNJ-77242113 Dose 3 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
Drug: JNJ-77242113
Participants originally randomized to JNJ-77242113 Dose 1 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 BID from Week 0 through Week 36 in this study.
Drug: JNJ-77242113
Participants originally randomized to JNJ-77242113 Dose 3 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 BID from Week 0 through Week 36 in this study.
Drug: JNJ-77242113
Participants originally randomized to placebo in originating Study 77242113PSO2001 will receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.
Drug: JNJ-77242113
JNJ-77242113 tablet will be administered orally.
Percentage of Participants Who Achieved Greater Than or Equal to (>=) 75 Percent (%) Improvement From Baseline in Psoriasis Area Severity Index Score (PASI-75) at LTE Week 36
Percentage of participants who achieved \>=75% improvement from baseline in PASI score at LTE Week 36 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1=slight, 2=moderate, 3=severe, 4=very severe) and extent of involvement from 0 (no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
Time frame: Baseline (Week 0 of originating study 77242113PSO2001), LTE Week 36 (52 weeks from originating study baseline)
Percentage of Participants Who Achieved at Least 90% Improvement From Baseline in PASI Score (PASI-90) at LTE Week 36
Percentage of participants who achieved \>=90% improvement from baseline in PASI score at LTE Week 36 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1=slight, 2=moderate, 3=severe, 4=very severe) and extent of involvement from 0 (no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
Time frame: Baseline (Week 0 of originating study 77242113PSO2001), LTE Week 36 (52 weeks from originating study baseline)
Percentage of Participants Who Achieved 100% Improvement From Baseline in PASI Score (PASI-100) at LTE Week 36
Percentage of participants who achieved 100% improvement from baseline in PASI score at LTE Week 36 was reported. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1=slight, 2=moderate, 3=severe and 4=very severe) and extent of involvement from 0 (no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range on a scale of 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
Time frame: Baseline (Week 0 of originating study 77242113PSO2001), LTE Week 36 (52 weeks from originating study baseline)
Change From Baseline in PASI Total Score at LTE Week 36
Change from baseline in PASI total score at LTE Week 36 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
Time frame: Baseline (Week 0 of originating study 77242113PSO2001), LTE Week 36 (52 weeks from originating study baseline)
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at LTE Week 36
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>)1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
Time frame: At LTE Week 36 (52 weeks from originating study baseline)
Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores at LTE Week 36
Change from baseline in PSSD symptoms scores at LTE Week 36 was reported. PSSD was a patient-reported outcome (PRO) questionnaire designed to measure severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD: self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical scales for severity. Items were averaged on the daily symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales were answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0=least severe and 100=most severe. Higher score indicated more severe disease. Baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
Time frame: Baseline (Week 0 of originating study 77242113PSO2001), LTE Week 36 (52 weeks from originating study baseline)
Change From Baseline in PSSD Signs Score at LTE Week 36
Change from baseline in PSSD sign scores at LTE Week 36 was reported. PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily sign score when at least 3 items (\>=50 percentage of 6 items) on these scales were answered. The average value was converted into 0-100 scoring, such that sign score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
Time frame: Baseline (Week 0 of originating study 77242113PSO2001), LTE Week 36 (52 weeks from originating study baseline)
Percentage of Participants Who Achieved PSSD Symptoms Score Equal (=) 0 at LTE Week 36 Among Participants With a Baseline (Week 0 of the Originating Study) Symptoms Score >=1
The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value is converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
Time frame: Baseline (Week 0 of originating study 77242113PSO2001), LTE Week 36 (52 weeks from originating study baseline)
Percentage of Participants Achieving PSSD Signs Score=0 at Week 36 Among Participants With a Baseline (Week 0 of the Originating Study) Signs Score >=1
The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily sign score when at least 3 items (\>=50 percentage of 6 items) on these scales are answered. The average value is converted into 0-100 scoring, such that sign score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
Time frame: Baseline (Week 0 of originating study 77242113PSO2001), LTE Week 36 (52 weeks from originating study baseline)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation where participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TEAE was defined as any AE that occurred after receiving the treatment in originating study (77242113PSO2001). TEAEs and TESAEs that occurred during this study are reported.
Time frame: From LTE Week 0 up to LTE Week 40
| Milestone | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Started | 35 | 35 | 39 | 40 | 40 | 38 |
| Completed | 29 | 27 | 33 | 30 | 33 | 35 |
| Not completed | 6 | 8 | 6 | 10 | 7 | 3 |
| Withdrew: Withdrawal by subject | 5 | 4 | 3 | 7 | 4 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 2 | 1 | 1 |
| Withdrew: Other | 1 | 2 | 2 | 1 | 2 | 1 |
Percentage of participants who achieved \>=75% improvement from baseline in PASI score at LTE Week 36 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1=slight, 2=moderate, 3=severe, 4=very severe) and extent of involvement from 0 (no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
| Percentage of participants | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Greater Than or Equal to (>=) 75 Percent (%) Improvement From Baseline in Psoriasis Area Severity Index Score (PASI-75) at LTE Week 36 | 65.7 | 48.8 | 69.8 | 58.5 | 65.1 | 76.2 |
Percentage of participants who achieved \>=90% improvement from baseline in PASI score at LTE Week 36 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1=slight, 2=moderate, 3=severe, 4=very severe) and extent of involvement from 0 (no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
| Percentage of participants | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved at Least 90% Improvement From Baseline in PASI Score (PASI-90) at LTE Week 36 | 57.1 | 27.9 | 41.9 | 36.6 | 51.2 | 64.3 |
Percentage of participants who achieved 100% improvement from baseline in PASI score at LTE Week 36 was reported. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1=slight, 2=moderate, 3=severe and 4=very severe) and extent of involvement from 0 (no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range on a scale of 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
| Percentage of participants | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved 100% Improvement From Baseline in PASI Score (PASI-100) at LTE Week 36 | 34.3 | 14.0 | 20.9 | 17.1 | 25.6 | 40.5 |
Change from baseline in PASI total score at LTE Week 36 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
| Units on a scale | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in PASI Total Score at LTE Week 36 | -14.15 ± 8.068 | -13.55 ± 8.232 | -14.45 ± 6.878 | -13.24 ± 8.981 | -15.81 ± 8.908 | -18.46 ± 7.892 |
The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>)1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.
| Percentage of participants | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at LTE Week 36 | 65.7 | 37.2 | 60.5 | 46.3 | 60.5 | 73.8 |
Change from baseline in PSSD symptoms scores at LTE Week 36 was reported. PSSD was a patient-reported outcome (PRO) questionnaire designed to measure severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD: self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical scales for severity. Items were averaged on the daily symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales were answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0=least severe and 100=most severe. Higher score indicated more severe disease. Baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
| Units on a scale | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores at LTE Week 36 | -29.5 ± 25.59 | -30.1 ± 28.09 | -35.2 ± 30.81 | -31.2 ± 28.48 | -29.4 ± 27.41 | -47.7 ± 28.04 |
Change from baseline in PSSD sign scores at LTE Week 36 was reported. PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily sign score when at least 3 items (\>=50 percentage of 6 items) on these scales were answered. The average value was converted into 0-100 scoring, such that sign score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
| Units on a scale | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in PSSD Signs Score at LTE Week 36 | -42.8 ± 28.65 | -35.2 ± 29.02 | -39.2 ± 31.64 | -36.6 ± 29.16 | -43.1 ± 26.87 | -53.1 ± 22.03 |
The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value is converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
| Percentage of participants | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved PSSD Symptoms Score Equal (=) 0 at LTE Week 36 Among Participants With a Baseline (Week 0 of the Originating Study) Symptoms Score >=1 | 34.3 | 18.6 | 21.4 | 17.1 | 30.2 | 26.2 |
The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily sign score when at least 3 items (\>=50 percentage of 6 items) on these scales are answered. The average value is converted into 0-100 scoring, such that sign score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of first study drug administration date in 77242113PSO2001 study.
| Percentage of participants | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving PSSD Signs Score=0 at Week 36 Among Participants With a Baseline (Week 0 of the Originating Study) Signs Score >=1 | 22.9 | 16.3 | 11.6 | 12.2 | 14.0 | 16.7 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation where participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TEAE was defined as any AE that occurred after receiving the treatment in originating study (77242113PSO2001). TEAEs and TESAEs that occurred during this study are reported.
| Participants | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| TEAEs | 23 | 18 | 19 | 27 | 27 | 19 |
| TESAEs | 1 | 0 | 2 | 3 | 2 | 1 |
Collected over From LTE Week 0 up to LTE Week 40. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Then JNJ-77242113 100 mg QD | 0/35 (0%) | 1/35 (2.9%) | 14/35 (40%) |
| JNJ-77242113 25 mg QD | 0/35 (0%) | 0/35 (0%) | 13/35 (37.1%) |
| JNJ-77242113 50 mg QD | 0/39 (0%) | 2/39 (5.1%) | 15/39 (38.5%) |
| JNJ-77242113 25 mg BID | 0/40 (0%) | 3/40 (7.5%) | 17/40 (42.5%) |
| JNJ-77242113 100 mg QD | 0/40 (0%) | 2/40 (5%) | 20/40 (50%) |
| JNJ-77242113 100 mg BID | 0/38 (0%) | 1/38 (2.6%) | 15/38 (39.5%) |
| Event | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| Cerebrovascular AccidentNervous system disorders | 1/35 | 0/35 | 0/39 | 0/40 | 0/40 | 0/38 |
| Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/35 | 0/35 | 0/39 | 0/40 | 0/40 | 1/38 |
| Coronary Artery DiseaseCardiac disorders | 0/35 | 0/35 | 1/39 | 0/40 | 0/40 | 0/38 |
| Non-Cardiac Chest PainGeneral disorders | 0/35 | 0/35 | 1/39 | 0/40 | 0/40 | 0/38 |
| Foot DeformityMusculoskeletal and connective tissue disorders | 0/35 | 0/35 | 1/39 | 0/40 | 0/40 | 0/38 |
| Ventricular DysfunctionCardiac disorders | 0/35 | 0/35 | 0/39 | 1/40 | 0/40 | 0/38 |
| DiverticulitisInfections and infestations | 0/35 | 0/35 | 0/39 | 0/40 | 1/40 | 0/38 |
| Ligament InjuryInjury, poisoning and procedural complications | 0/35 | 0/35 | 0/39 | 1/40 | 0/40 | 0/38 |
| Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders | 0/35 | 0/35 | 0/39 | 0/40 | 1/40 | 0/38 |
| Tonsillar HypertrophyRespiratory, thoracic and mediastinal disorders | 0/35 | 0/35 | 0/39 | 1/40 | 0/40 | 0/38 |
| Event | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 9/35 | 3/35 | 7/39 | 6/40 | 11/40 | 5/38 |
| Upper Respiratory Tract InfectionInfections and infestations | 4/35 | 6/35 | 3/39 | 3/40 | 2/40 | 4/38 |
| Covid-19Infections and infestations | 2/35 | 1/35 | 3/39 | 1/40 | 2/40 | 3/38 |
| BronchitisInfections and infestations | 1/35 | 1/35 | 3/39 | 1/40 | 0/40 | 0/38 |
| InfluenzaInfections and infestations | 1/35 | 0/35 | 1/39 | 3/40 | 1/40 | 1/38 |
| HeadacheNervous system disorders | 0/35 | 2/35 | 0/39 | 3/40 | 3/40 | 0/38 |
| Urinary Tract InfectionInfections and infestations | 2/35 | 1/35 | 1/39 | 1/40 | 0/40 | 2/38 |
| Alanine Aminotransferase IncreasedInvestigations | 2/35 | 1/35 | 1/39 | 0/40 | 0/40 | 2/38 |
| Aspartate Aminotransferase IncreasedInvestigations | 1/35 | 1/35 | 1/39 | 0/40 | 0/40 | 2/38 |
| VomitingGastrointestinal disorders | 0/35 | 0/35 | 0/39 | 0/40 | 2/40 | 0/38 |
| Age, Continuous(Years) | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Mean | 44.3 ± 13.96 | 45.1 ± 12.43 | 44.6 ± 9.51 | 46.1 ± 11.75 | 43.8 ± 14.03 | 41.6 ± 11.71 | 44.2 ± 12.25 |
| Sex: Female, Male(Participants) | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Female | 15 | 9 | 15 | 11 | 10 | 11 | 71 |
| Male | 20 | 26 | 24 | 29 | 30 | 27 | 156 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 4 | 3 | 3 | 2 | 17 |
| Not Hispanic or Latino | 32 | 32 | 34 | 36 | 37 | 36 | 207 |
| Unknown or Not Reported | 0 | 1 | 1 | 1 | 0 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 2 | 1 | 1 | 0 | 4 |
| Asian | 5 | 9 | 9 | 7 | 7 | 8 | 45 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| Black or African American | 0 | 0 | 0 | 2 | 0 | 1 | 3 |
| White | 30 | 25 | 27 | 27 | 32 | 28 | 169 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 | 1 | 0 | 1 | 4 |
| Region of Enrollment(Participants) | Placebo Then JNJ-77242113 100 mg QD | JNJ-77242113 25 mg QD | JNJ-77242113 50 mg QD | JNJ-77242113 25 mg BID | JNJ-77242113 100 mg QD | JNJ-77242113 100 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Canada | 7 | 6 | 4 | 7 | 5 | 5 | 34 |
| France | 0 | 1 | 2 | 1 | 0 | 1 | 5 |
| Germany | 6 | 6 | 5 | 7 | 9 | 5 | 38 |
| Japan | 3 | 2 | 3 | 3 | 4 | 4 | 19 |
| Poland | 6 | 9 | 11 | 9 | 12 | 10 | 57 |
| Korea, South | 1 | 2 | 3 | 1 | 1 | 3 | 11 |
| Spain | 2 | 1 | 1 | 2 | 1 | 1 | 8 |
| Taiwan | 1 | 4 | 3 | 3 | 2 | 0 | 13 |
| United Kingdom | 2 | 0 | 0 | 0 | 0 | 1 | 3 |
| United States | 7 | 4 | 7 | 7 | 6 | 8 | 39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Jun 2022 to primary completion in Sep 2023, 15 months.
Results were first posted in Jun 2026, 2 years 8 months after primary completion. A results delay was requested in Sep 2024.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 15 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Icotrokinra
Janssen Research & Development, LLC →